Document Detail

Pilot study of etanercept in patients with relapsed cutaneous T-cell lymphomas.
MedLine Citation:
PMID:  15280837     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Tumor necrosis factor (TNF)-alpha has been implicated in the pathogenesis of cutaneous T-cell lymphoma (CTCL). OBJECTIVE: To assess the toxicity, safety, and efficacy of etanercept (soluble TNF receptor) in patients with relapsed CTCL. METHODS: Etanercept was administered twice weekly at a dose of 25 mg subcutaneously. Patients with improvement after two months could be continued on treatment. RESULTS: Twelve out of the 13 patients enrolled on study were evaluable (Stage I-IIA, 3 patients; Stage IIB-IV disease, 9 patients). The median number of previous therapies was 7 (range, 3-12). Etanercept induced partial remission in one patient (8%) and minor response in one patient (8%), both of whom had Stage IB disease. Most patients experienced no side effects. CONCLUSION: This pilot study suggests that etanercept is safe and generally well tolerated in patients with CTCL. The effect of etanercept in a larger cohort of patients with early disease merits investigation.
Apostolia-Maria Tsimberidou; Francis J Giles; Madeleine Duvic; Razelle Kurzrock
Related Documents :
7816257 - Interleukin-8 in chronic renal failure and dialysis patients.
18930517 - Elevated granulocyte colony-stimulating factor levels predict treatment failure in pati...
20953817 - Predictive value of c-reactive protein on 30-day and 1-year mortality in acute coronary...
19591197 - Elevated procalcitonin and c-reactive protein as potential biomarkers of sepsis in a su...
2439997 - Effect of propranolol on ventricular rate during atrial fibrillation in the wolff-parki...
22341987 - Movement analysis of upper extremity hemiparesis in patients with cerebrovascular disea...
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of the American Academy of Dermatology     Volume:  51     ISSN:  1097-6787     ISO Abbreviation:  J. Am. Acad. Dermatol.     Publication Date:  2004 Aug 
Date Detail:
Created Date:  2004-07-28     Completed Date:  2004-09-28     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7907132     Medline TA:  J Am Acad Dermatol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  200-4     Citation Subset:  IM    
Department of Leukemia, University of Texas, M. D. Anderson Cancer Center, Houston, TX 77030, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Drug Administration Schedule
Immunoglobulin G / administration & dosage*,  adverse effects
Injections, Subcutaneous
Lymphoma, T-Cell, Cutaneous / drug therapy*,  pathology
Middle Aged
Neoplasm Recurrence, Local / drug therapy*
Neoplasm Staging
Pilot Projects
Receptors, Tumor Necrosis Factor / administration & dosage*
Skin Neoplasms / drug therapy*,  pathology
Treatment Outcome
Reg. No./Substance:
0/Immunoglobulin G; 0/Receptors, Tumor Necrosis Factor; 185243-69-0/TNFR-Fc fusion protein

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The reliability of horizontally sectioned scalp biopsies in the diagnosis of chronic diffuse telogen...
Next Document:  Association of porphyria cutanea tarda with hereditary hemochromatosis.